Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis

IDrugs

Volumn 13, Issue 12, 2010, Pages 911-920

  Cheah, Benjamin C ^a   Kiernan, Matthew C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; KNS 760704; PLACEBO; PRAMIPEXOLE; RILUZOLE; UBIQUITIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; CREATININE BLOOD LEVEL; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENANTIOMER; EXCITOTOXICITY; HALLUCINATION; HEART RATE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATENT; QT INTERVAL; RASH; RESTLESS LEGS SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUGS, INVESTIGATIONAL; HUMANS; ISOMERISM;

EID: 79952758621     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Beneft of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED Ann neu ROl 1996 39 2 147-157 (Pubitemid 26071564)
2. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z et al Nature 1993 362 6415 59-62 (Pubitemid 23087289)
3. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF nAt MeD 1999 5 3 347-350 (Pubitemid 29124375)
4. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W et al Jama-J Am Med Assoc 2002 287 13 1653-1661 (Pubitemid 34289217)
5. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S et al Nature 2002 417 6884 74-78 (Pubitemid 34498818)
6. A clinical trial of creatine in ALS. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J et al Neurology 2004 63 9 1656-1661 (Pubitemid 39507584)
7. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A euR J PhARMACOl 2007 557 2-3 132-140 (Pubitemid 46186283)
8. Knopp Neurosciences Inc Knopp Neurosciences Inc COMPAny WORlD WiDe Web Site 2007 September 24
9. NCT00140218:/?(+) pramipexole in early amyotrophic lateral sclerosis. CliniCAltRiAlS.gOv 2005 August 30
10. Pramipexole prevents neurotoxicity induced by oligomers of-amyloid. Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M euR J PhARMACOl 2007 569 3 194-196 (Pubitemid 47198246)
11. NCT00647296: Safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (ALS) (CL201). Clini CAltRiAlS.gOv 2008
12. Intensive blood pressure safety monitoring following single-and multiple-dose administration of KNS-760704 in healthy volunteers. Graham CF, Mather JL, Ingersoll EW, Hebrank GT, Bozik ME J Clin PhARMACOl 2008 48 9 Abs 38
13. Safety, tolerability, and pharmacokinetics of single and multiple doses of KNS-760704 in healthy volunteers. Graham CF, Mather JL, Ingersoll EW, Kramer WG, Hebrank GT, Bozik ME J Clin PhARMACOl 2008 48 9 Abs 37
14. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J et al Nature 2005 434 7033 658-662 (Pubitemid 40488559)
15. KNS-760704 [(6/?)-4,5,6,7-tetrahydro-/V6-propyl-2, 6-benzothiazole- diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. Gribkoff VK, Bozik ME CnS neuROSCi theR 2008 14 3 215-226
16. Effcacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE et al Lancet Neurol 2007 6 12 1045-1053 (Pubitemid 350116691)
17. The mitochondrial permeability transition pore: A molecular target for amyotrophic lateral sclerosis therapy. Martin LJ bi OChiM biOPhyS ACtA MOl bASiS DiS 2010 1802 1 186-197
18. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM Ann neu ROl 1999 46 5 787-790 (Pubitemid 29518143)
19. KNS-760704-CL201, part 1: A 12-week phase 2 study of the safety, tolerability, and clinical effects of KNS 760704 in ALS subjects. Bozik M, Ingersoll E, Volles L, Mather J, Amburgey C, Moritz J, Archibald D, Sullivan M, Gribkoff V, Miller R, Mitsumoto H et al AMyOtROPhiC lAteRAl SCleR 2009 20 December 8-10 Abs C40
20. Preliminary safety and pharmacokinetic results following administration of ascending single doses of KNS-760704 to healthy volunteers. Graham CF, Mather JL, Ingersoll E, Kramer WG et al AMyOtROPhiC lAteRAl SCleR 2007 18 December 1-3 Abs SW303
21. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-L-propylamino-benzathiazole dihydrochloride]. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-Ciossek C, Kussmaul L J PhARMACOl exP theR 2006 316 1 189-199 (Pubitemid 41832596)
22. R+ pramipexole as a mitochondrially focused neuroprotectant: Initial early phase studies in ALS. Wang H, Larriviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, Lacomis D, Pattee GL, Phillips LH, Solenski NJ, Zivkovic SA et al Amyotrophic Lateral Scler 2008 9 1 50-58 (Pubitemid 351260373)
23. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. Ferrari-Toninelli G, Maccarinelli G, Uberti D, Buerger E, Memo M bMC PhARMACOl 2010 10 2
24. Göttingen minipigs as the nonrodent species in the IND for KNS-760704. Frantz SW, Demady DR, Dalton JA, Popke EJ, Tasker EJ, Ingersoll E, Gribkoff VK int J tOxiCOl 2010 29 1 Abs P17
25. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or β amyloid peptide in SH-SY5Y neuroblastoma. Abramova NA, C assarino DS, Khan SM, Painter TW, Bennett JP J neuROSCi ReS 2002 67 4 494-500 (Pubitemid 34117119)
26. Rats treated with KNS-760704 show a favorable safety and toxicology profle with high brain: Plasma levels that support clinical development in amyotrophic lateral sclerosis. Demady DR, Popke EJ, Lindahl RG, Dalton JA, Frantz SW, Ingersoll EW, Gribkoff VK Annu Meet SOC tOxiCOl 2009 48 March Abs 2055
27. Biogen Idec and Knopp Neurosciences announce license agreement for late-stage ALS drug candidate. Biogen Idec Inc PReSS ReleASe 2010 August 18
28. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JHJ, Franssen H, van den Berg LH Ann neu ROl 2003 53 4 437-445 (Pubitemid 36373255)
29. Motor neurone disease: A Pandora's box. Kiernan MC MeD J AuSt 2003 178 7 311-312 (Pubitemid 36503088)
30. Assessment of disease progression in motor neuron disease. Winhammar JMC, Rowe DB, Henderson RD, Kiernan MC lAnCet neu ROl 2005 4 4 229-238 (Pubitemid 40381110)
31. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG, Mitchell JD, Lyon M, Moore DH COChRAne DAtAbASe SySt Rev 2007 1 CD001447
32. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Cheah BC, Vucic S, Krishnan AV, Kiernan MC CuRR MeD CheM 2010 17 18 1942-1959
33. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Urbani A, Belluzzi O euR J neuROSCi 2000 12 10 3567-3574
34. Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Kiernan MC exP neuROl 2009 218 1 1-4
35. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Vucic S, Kiernan MC CuRR MOl MeD 2009 9 3 255-272
36. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Shi P, Gal J, Kwinter DM, Liu X, Zhu H biOChiM biOPhyS ACtA 2010 1802 1 45-51
37. Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Holloway RG, Shoulson I, Kieburtz K, McDermott M, Shinaman A, Kamp C, Fahn S, Lang A, Marek K, Seibyl J, Welsh M et al ARCh neuROl 2004 61 7 1044-1053 (Pubitemid 38915945)
38. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Segura-Aguilar J, Metodiewa D, Welch CJ Biochim Biophys Acta Gen Subj 1998 1381 1 1-6 (Pubitemid 28248110)
39. Dopamine autoreceptor agonists: Resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. Schneider CS, Mierau J J MeD CheM 1987 30 3 494-498 (Pubitemid 17033654)
40. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian neurotoxin methylpyridinium ion. Cassarino DS, Fall CP, Smith TS J Neurochem 1998 71 1 295-301 (Pubitemid 28292562)
41. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. Sayeed I, Parvez S, Winkler-Stuck K, Seitz G, Trieu I, Wallesch C-W, Schonfeld P, Siemen D FASeb J 2006 20 1 556
42. Pramipexole protects against H O-induced PC12 cell death. Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M nAunyn SChMieDebeRgS ARCh PhARMACOl 2006 372 4 257-266 (Pubitemid 43123953)
43. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W liFe SCi 1999 64 15 1275-1285 (Pubitemid 29156855)
44. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Gu M, Irvani M, Cooper JM, King D, Jenner P, Schapira AHV J neuROCheM 2004 91 5 1075-1081 (Pubitemid 39587446)
45. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. Le WD, Jankovic J, Xie W, Appel SH J neuRAl tRAnSM 2000 107 10 1165-1173
46. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the infammatory response. Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Schapira AH, Jenner P exP neuROl 2008 212 2 522-531
47. Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. Kiernan MC J PhySiOl lOnDOn 2009 587 15 3759-3760
48. 3 receptors. Wong SK, Shrikhande A AbStR SOC neuROSCi 2003 33 November 8-12 Abs 363.4
49. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Pattee GL, Post GR, Gerber RE, Bennett JP AMyOtROPhiC lAteRAl SCleROSiS OtheR MOtOR neuROn DiSORD 2003 4 2 90-95 (Pubitemid 36874777)
50. Progression in ALS is not linear but is curvilinear. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V J neuROl 2010 257 10 1713-1717
51. Knopp Neurosciences reports presentation of encouraging clinical trends in a phase 2 study of KNS-760704 in ALS. Knopp Neurosciences PReSS ReleASe 2009
52. Knopp Neurosciences presents further encouraging trends in its phase 2 study of KNS-760704 (Dexpramipexole) in ALS. Knopp Neurosciences PReSS ReleASe 2010
53. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, Mendoza M, Mass J, Kushner G, Miller RG neuROlOgy 2004 62 10 1845-1847 (Pubitemid 38661748)
54. Phase II trial of CoQ10 for ALS fnds insuffcient evidence to justify phase III. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E et al Ann Neu Rol 2009 66 2 235-244
55. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, van der Burg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P et al SCienCe 2009 323 5918 1205-1208
56. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J et al SCienCe 2009 323 5918 1208-1211
57. FUS mutations in amyotrophic lateral sclerosis: Clinical, pathological, neurophysiological and genetic analysis. Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, Blumbergs PC, Vucic S, Kiernan MC, Nicholson GA J neuROl neuROSuRg PSyChiAtRy 2010 81 6 639-645
58. Mutations of optineurin in amyotrophic lateral sclerosis. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O et al nAtuRe 2010 465 7295 223-226
59. Mitochondrial apoptosis without VDAC Galluzzi L, Kroemer G nAt Cell bi Ol 2007 9 5 487-489 (Pubitemid 46696528)
60. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC nAtuRe 2004 427 6973 461-465 (Pubitemid 38168501)
61. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V, Cleveland DW neuROn 2010 67 4 575-587
62. Glucose control and vascular complications in veterans with type 2 diabetes. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR et al Nengl J Med 2009 360 2 129-139
63. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW J Clin PhARMACOl 2010 DOI: 10.1177/0091270010379412
64. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Hasegawa M, Ara T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I et al Ann Neu Rol 2008 64 1 60-70
65. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF et al Nat Genet 2008 40 5 572-574 (Pubitemid 351601218)
66. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Biglan KM, Holloway R, Marek K, Dick A, Fahn S, Julian-Baros E, Kamp C, Kieburtz K, Lang A, McDermott M, Seibyl J et al Arch Neurol 2009 66 5 563-570
67. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Matthews RT, Yang LC, Browne S, Baik M, Beal MF PROC nAtl ACAD SCi uSA 1998 95 15 8892-8897
68. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS AMyOtROPh lAteRAl SCleR 2008 9 5 266-272